Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2336327 | 1.00 | KMT2A (0.45) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL8024204 | 0.88 | MEN1 (0.39) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL29012636 | 0.85 | CA1 (0.41) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL8422179 | 0.84 | TSHR (0.39) | KMT2AMEN1ALDH1A1LMNATSHR | |
| SCHEMBL3355256 | 0.84 | TSHR (0.39) | KMT2AMEN1ALDH1A1LMNATSHR | |
| SCHEMBL8418425 | 0.84 | TSHR (0.39) | KMT2AMEN1ALDH1A1LMNATSHR | |
| SCHEMBL8090761 | 0.82 | SMN1; SMN2 (0.44) | KMT2AMEN1SMN1; SMN2TSHRCA14 | |
| SCHEMBL11336105 | 0.82 | KMT2A (0.41) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4778798 | 0.81 | TSHR (0.36) | KMT2AMEN1ALDH1A1TSHRMMP1 | |
| SCHEMBL11134509 | 0.81 | ALDH1A1 (0.37) | KMT2AMEN1ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2189442-B1 | Process and intermediates for the preparation of aliskiren | KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) | 2014-10-01 | — | — | EP | disclosed |
| US-20100184998-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100184998-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| EP-2189442-A1 | Process and intermediates for the preparation of aliskiren | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2010-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184998-A1 | ORGANIC COMPOUNDS | CYP1B1, CYP3A7, CYP2F1 | KMT2A 4471/4885MEN1 289/4885SMN1; SMN2 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.